Sector
FDA Regulatory Shift Signals New Path Forward for uniQure's Huntington's Disease Therapy
uniQure (QURE) surged after the FDA agreed that three-year clinical data may support an accelerated approval filing for AMT-130, reopening a regulatory pathway that had appeared uncertain just months ago.